Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants. We investigated initial drug-drug interactions between lamotrigine and sertraline. We report on case histories of two epileptic patients who were initially on lamotrigine and to whom sertraline was added to control psychiatric features. In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity. In case 2, a 25 mg reduction in the total daily dose of sertraline resulted in halving of the lamotrigine blood level even though the lamotrigine dosage was increased by 33%. This shows that sertraline has potent interactions with lamotrigine metabolism. The authors hypothesize that inhibition of glucuronidation is responsible. Clinicians are advised to observe for symptoms of toxicity and to do serial blood levels to monitor this interaction.
INTRODUCTION
The combined use of antidepressants and anticonvulsants is of growing concern as increasing pharmaceutical agents are released with increased indications. Antidepressants are utilized in the epilepsy population to treat affective disorders, schizoaffective disorders, obsessive compulsive disorders and intermittent explosive disorders 1'2. A growing list of anticonvulsants is being utilized to treat bipolar and schizoaffective disorders in conjunction with antidepressants and neuroleptics 3'4. In the past, the greatest concern was the effect of the psychotropic upon seizure threshold. Although drugdrug interactions have been considered, these usually focused upon agents within one therapeutic family--anticonvulsant interactions or psychotropic interactions. The potential for toxic interactions among antidepressants and anticonvulsants has not been widely appreciated.
Within the past decade, a series of serotonergic specific re-uptake inhibitors (SSRIs) have been released. Some of these SSRIs are noted to have potent cytochrome P450 inhibition with expected drug-drug interactions 5. Two cases are described wherein the epileptic patient had been maintained on lamotrigine and with the addition of sertraline toxic effects with increased blood levels were noted (Table l) .
CASE1
RH is a 39 year old single white female who developed post-traumatic epilepsy with cluster seizures which had relatively poor response to phenobarbital, carbamazepine, felbamate, and valproic acid. The patient had been maintained on lamotrigine 200 mg total daily dose when initially evaluated in psychiatric consultation. The baseline lamotrigine blood level was 2.5 /zg/ml. The patient was diagnosed as hav-1059-1311/98/020163 + 03 $12.00/0 ~ 1998 British Epilepsy Association ing post-traumatic intermittent explosive disorder 6. A total daily dose of 25 mg of sertraline was prescribed. Although the patient's irritability began to diminish, she complained of increasing confusion and cognitive impairment. A significant increase in lamotrigine blood level (5.1 /zg/ml) was noted 6 weeks following the addition of sertraline. Thereafter, the patient's sertraline was increased to 50 mg daily with total control of explosive features to a point where the patient commented that she had returned to her pre-accident psychiatric baseline. At the same time, the patient's lamotrigine was decreased to 100 mg daily. On this lower lamotrigine dosage, the patient's confusion and impaired cognition cleared within 3 weeks. Even though the lamotrigine was only half of what had been initially prescribed, the blood level remained higher (3.1 #g/ml) with significant reduction in her cluster seizures.
CASE 2
MH is a 17 year old single white female with a mixed epileptic disorder including petit mal, grand mal, and complex partial seizures with secondary generalization which had an incomplete response to phenobarbital, phenytoin, valproic acid, and felbamate. At the time of the initial psychiatric consultation, the patient had been maintained on a total daily dose of 450 mg of lamotrigine with incomplete control of seizures. The patient's psychiatric history included three admissions, multiple suicide attempts, complete vegetative-affective cluster, oppositional defiant behaviour, explosivity with poor impulse control, and questionable attention deficit disorder. When seen in psychiatric consultation, the patient was diagnosed as having an organic mood disorder secondary to epilepsy, intermittent explosive disorder, and conduct disorder 6. Historically the patient's affective symptoms had shown some stabilization with valproic acid. The patient underwent a lithium trial of 600 mg daily with a decrease in explosivity and mood swings. Decreased memory, imbalance and tremors were noted which necessitated discontinuation of the lithium. Sertraline was initiated and titrated to 75 mg daily with decreased severity of affective symptoms and explosivity. No side effects were noted. After being on sertraline for 6 weeks, the lamotrigine was increased to 600 mg daily with decreased seizure frequency. On this combined regimen, the patient's behaviour was markedly improved with no violent or explosive episodes. Six weeks after the lamotrigine dosage had been increased, the patient complained of marked sedation, fatigue, and decreased cognition. The lamotrigine blood level was 19.3 /zg/ml, the sertraline blood level was nondetectable, and the desmethylsertraline blood level was 24.0 ng/ml. It was felt that a drug-drug interaction similar to the previous case had occurred and the desire was to minimize toxicity yet to maintain a lamotrigine blood level higher than what would have occurred at the initiation of therapy when the patient's seizures were not totally controlled. Therefore, the lamotrigine dosage was increased to 800 mg daily and the sertraline dosage was decreased to 50 mg daily. After 2.5 weeks on this new regime, the patient had continued seizure control, no explosivity, decreased sedation, decreased fatigue, and clearer cognition. The repeat lamotrigine blood level was 9.8 ~zg/ml with sertraline and desmethylsertraline blood levels both nondetectable. With a 33% reduction in the sertraline daily dose, the lamotrigine blood level decreased by approximately 50%, even though the lamotrigine daily dose had been increased by 33%.
DISCUSSION
The drug--drug interaction noted in these two cases is most striking. In both, toxic symptoms occurred with fatigue, sedation, confusion and decreased cognition as principal symptoms. These symptoms were resolved with reduced sertraline dosage and concomitant decreased lamotrigine blood levels. As sertraline is an inhibitor of cytochrome P450 isoenzymes, especially IID6, it was expected that the interaction would be through such a mechanism. However, lamotrigine is primarily metabolized through glucuronidation 7. The metabolic pathways for sertraline include Ndemethylation, hydroxylation, oxidative deamination, and glucuronidation 8. Similar to the valproic acid inhibition of lamotrigine metabolism, it is hypothe-sized that sertraline reduces lamotrigine glucuronidation through competitive inhibition with resultant increased blood levels 9. Another potential mechanism would be the direct inhibition of other metabolic processes.
It is clear that further clinical research on the interactions between these two drugs is indicated. Until it can be clearly established which mechanism exists, the authors recommend caution when prescribing sertraline or other SSRIs with lamotrigine. Appropriate therapeutic drug monitoring is necessary and should prevent any unnecessary toxicity. The authors further recommend that any agent which has a metabolic pathway including glucuronidation could result in increased lamotrigine blood levels, toxicity, and potentially an increased risk for fatal lamotrigine rashes (especially during the first 6 months of lamotrigine therapy)l°-12.
